Description: Auxilium Pharmaceuticals Inc.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, rheumatologists, and orthopedic, general, and plastic surgeons primarily in the United States. The company markets Testim, a topical 1% testosterone gel for the treatment of hypogonadism; and XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of DupuytrenÂ’s contracture. The company also develops XIAFLEX, which is in Phase II clinical trials for the treatment of PeyronieÂ’s disease and Adhesive Capsulitis. In addition, its product pipeline includes AA4010 that is in Phase I clinical trials for the treatment for overactive bladder using its transmucosal film delivery system; and A Fentanyl, a pain product, which is under Phase I clinical trials. In addition, the company has rights to develop other compounds for the treatment of pain using its transmucosal film delivery system; and other products for the treatment of urologic disease and hormone replacement using its transmucosal film technology. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.